Combined treatment of advanced primary hepatocellular carcinoma with traditional Chinese medicine and Western medicine

1997 ◽  
Vol 3 (2) ◽  
pp. 86-88
Author(s):  
Er-Xin Yu
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Western Medicine ◽  
Combined Treatment ◽  
Primary Hepatocellular Carcinoma

scholarly journals Long-Term Effectiveness of Combined Treatment with Traditional Chinese Medicine and Western Medicine on the Prognosis of Patients with Lung Cancer

2016 ◽  
Vol 22 (3) ◽  
pp. 212-222 ◽  
Author(s):  
Woung-Ru Tang ◽  
Sien-Hung Yang ◽  
Chih-Teng Yu ◽  
Chin-Chou Wang ◽  
Sheng-Teng Huang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Western Medicine ◽  
Combined Treatment

Effectiveness of Combined Treatment with Traditional Chinese Medicine and Western Medicine on the Prognosis of Patients with Breast Cancer

2020 ◽  
Vol 26 (9) ◽  
pp. 835-842 ◽  
Author(s):  
Yi-Chiao Lee ◽  
Yen-Hao Chen ◽  
Yu-Chuen Huang ◽  
Yun-Fang Lee ◽  
Ming-Yen Tsai
Keyword(s):  
Breast Cancer ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Western Medicine ◽  
Combined Treatment

scholarly journals Physical Therapy Modalities of Western Medicine and Traditional Chinese Medicine for Meibomian Gland Dysfunction

2020 ◽  
Vol 3 (4) ◽  
pp. 229-238
Author(s):  
Li Jie ◽  
Ou Shang-Kun ◽  
Li Wei ◽  
Liu Zu-Guo ◽  
Peng Qing-Hua
Keyword(s):  
Chinese Medicine ◽  
Physical Therapy ◽  
Traditional Chinese Medicine ◽  
Western Medicine ◽  
Meibomian Gland ◽  
Physical Therapy Modalities ◽  
Meibomian Gland Dysfunction

scholarly journals Effects of Shaoyao-Gancao-Fuzi Decoction on the Pharmacokinetics of CYP3A4-Mediated Tofacitinib in Rats

2020 ◽  
Author(s):  
Li Lin ◽  
Yuan Wang ◽  
Sennan Shao ◽  
Wen Lin ◽  
Dan Huang ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Oral Administration ◽  
Western Medicine ◽  
Control Group ◽  
Clinical Use ◽  
Pharmacokinetic Profiles ◽  
Pre Treatment ◽  
Cocktail Approach

Abstract Background: The combination of traditional Chinese medicine and western medicine is commonly accepted in clinics in China. Shaoyao-Gancao-Fuzi decoction (SGFD) has been extensively used to dispel wind, eliminate dampness and treat paralysis. Tofacitinib is approved for the treatment of rheumatoid arthritis. SGFD and tofacitinib could be used together for the treatment of rheumatoid arthritis.Methods: A cocktail approach was employed to assess the effects of SGFD on the activities of CYP450s. After pretreatment for 2 weeks with SGFD, a cocktail solution was given to rats 24 h after the last dose of saline or SGFD. Additionally, the pharmacokinetic profiles of oral administration of tofacitinib in rats, with or without SGFD pre-treatment were investigated.Results: The results showed that SGFD could induce the activity of CYP1A2 and inhibit the activity of CYP3A4. Furthermore, SGFD could significantly affect the pharmacokinetics of tofacitinib. Compared with control group, the AUC0-∞ of tofacitinib was increased from 13669.53 ± 4986.83 to 28706.69 ± 9563.13 ng/mL*h (p < 0.01), and the Cmax was increased from 8359.66 ± 1512.22 to 11332.51 ± 2791.90 ng/mL (p < 0.05).Conclusions: The system exposure of tofacitinib was increased by SGFD. The mechanism might be through inhibiting the activity of CYP3A4 and reducing the metabolism of tofacitinib in rats. The study will provide better guidance for the safe clinical use of SGFD and tofacitinib.

scholarly journals Determining novel candidate anti-hepatocellular carcinoma drugs using interaction networks and molecular docking between drug targets and natural compounds of SiNiSan

PeerJ ◽  
2021 ◽  
Vol 9 ◽  
pp. e10745
Author(s):  
Qin Zhang ◽  
Zhangying Feng ◽  
Mengxi Gao ◽  
Liru Guo
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Drug Targets ◽  
Cellular Response ◽  
Hormone Receptors ◽  
Enrichment Analysis ◽  
Stage Iii ◽  
Ppi Network ◽  
P53 Signaling

Background SiNiSan (SNS) is an ancient traditional Chinese medicine (TCM) used to treat liver and spleen deficiencies. We studied the unique advantages of using SNS to treat hepatocellular carcinoma (HCC) with multiple components and targets to determine its potential mechanism of action. Methods The active compounds from the individual herbs in the SNS formula and their targets were mined from Traditional Chinese Medicine Systems Pharmacology Database (TCMSP). HCC-associated targets were collected from the TCGA and GEO databases and samples were collected from patients with stage III hepatocellular carcinoma. A compound-disease target network was constructed, visualized, and analyzed using Cytoscape software. We built a protein-protein interaction (PPI) network using the String database. We enriched and analyzed key targets using GSEA, GO, and KEGG in order to explore their functions. Autodock software was used to simulate the process of SNS molecules acting on HCC targets. Results A total of 113 candidate compounds were taken from SNS, and 64 of the same targets were chosen from HCC and SNS. The predominant targets genes were PTGS2, ESR1, CHEK1, CCNA2, NOS2 and AR; kaempferol and quercetin from SNS were the principal ingredients in HCC treatment. The compounds may work against HCC due to a cellular response to steroid hormones and histone phosphorylation. The P53 signaling pathway was significantly enriched in the gene set GSEA enrichment analysis and differential gene KEGG enrichment analysis. Conclusions Our results showed that the SNS component has a large number of stage III HCC targets. Among the targets, the sex hormone receptors, the AR and ESR1 genes, are the core targets of SNS component and the most active proteins in the PPI network. In addition, quercetin, which has the most targets, can act on the main targets (BAX, CDK1, CCNB1, SERPINE1, CHEK2, and IGFBP3) of the P53 pathway to treat HCC.

Sign in / Sign up

Export Citation Format

Share Document